KLF9 and in situ carcinoma: In KLF9-overexpressing A375 cells, TMZ, CIS, or CARB had greater effects compared to naïve or ctrl-ad cells and significantly reduced cell viability to 65.73% (p ≤ 0.007), 64.93% (p ≤ 0.04), or 66.58 (p ≤ 0.04), respectively.